Nebivolol: Effects on the Liver and Kidneys

Nebivolol is a third-generation beta-blocker prescribed in the UK for high blood pressure and, in older patients, for stable chronic heart failure. It differs from older beta-blockers in being highly selective and in promoting nitric oxide release from blood vessels. Patients often ask how it affects the liver and kidneys, especially if they have other conditions or take supplements. This article summarises the evidence and the official product information.

What nebivolol is and how it works

Beta-blockers reduce the effect of adrenaline and noradrenaline on beta-adrenergic receptors. Nebivolol is highly selective for beta-1 receptors, which are found mainly in the heart, so it slows the heart rate and reduces the force of contraction with relatively little effect on beta-2 receptors in the airways.

Its second property distinguishes it from most other beta-blockers. Nebivolol stimulates endothelial nitric oxide production, probably through beta-3 receptors, causing blood vessels to relax. Münzel and Gori described it as a "somewhat different" beta-blocker for this reason.

Clinically, nebivolol lowers blood pressure and, in the SENIORS trial, reduced the combined outcome of death or cardiovascular hospital admission in people aged 70 and over with heart failure. In the UK, it is a prescription-only medicine.

Current NICE guidance on hypertension does not place beta-blockers among first-line treatments for most patients, but they remain important when there are additional indications, such as heart failure, angina or certain arrhythmias, or when other medicines are unsuitable.

How the liver processes nebivolol

Nebivolol is extensively metabolised in the liver, mainly by the enzyme CYP2D6, with contributions from other pathways. Several of its metabolites are themselves active. Elimination occurs via both urine and faeces, mostly as metabolites.

CYP2D6 activity varies considerably between people because of genetic differences. "Poor metabolisers" have much higher blood levels of the parent drug than "extensive metabolisers". However, because active metabolites compensate, the overall clinical effect appears broadly similar, and routine genetic testing is not required.

Because of this dependence on hepatic metabolism, the UK Summary of Product Characteristics lists hepatic insufficiency or impaired liver function as a contraindication. In practice, doctors avoid prescribing nebivolol to people with significant liver disease and usually choose an alternative.

Clinically significant liver injury caused by nebivolol appears to be rare in published reports. The concern is less that nebivolol damages the liver and more that a diseased liver cannot clear it predictably.

Nebivolol and the kidneys

Nebivolol is not primarily cleared unchanged by the kidneys, but kidney function still influences exposure to the drug and its metabolites. The product information therefore advises a lower starting dose in people with renal impairment, with careful adjustment by the prescriber, and notes limited experience in severe kidney disease.

From a protective perspective, controlling blood pressure is one of the most important ways to slow progression of chronic kidney disease. Any effective antihypertensive contributes to this. Some smaller studies have suggested that nebivolol's nitric oxide effects might offer additional benefits for kidney blood flow or protein leakage, but these findings are not established enough to change clinical practice.

For people with diabetic kidney disease or proteinuria, ACE inhibitors or angiotensin receptor blockers remain the recommended foundation of treatment, in line with European and UK guidance. Nebivolol may be added when needed for blood pressure or cardiac reasons.

Patients with kidney disease are usually monitored with regular blood tests for creatinine, estimated glomerular filtration rate and potassium. These tests relate mainly to the underlying condition and other medicines rather than to nebivolol specifically.

Interactions, monitoring and practical points

Because CYP2D6 is central to nebivolol's metabolism, medicines that strongly inhibit this enzyme can raise its levels. Examples include some antidepressants such as fluoxetine and paroxetine, and certain other drugs. Pharmacists check for these combinations when dispensing.

We also highlight dianabol gdje kupiti.

• Other blood pressure medicines may add to the lowering effect.
• Some calcium channel blockers, such as verapamil and diltiazem, can excessively slow the heart when combined with beta-blockers.
• Anti-inflammatory painkillers may blunt blood pressure control and stress the kidneys.
• Herbal products and stimulant supplements may interact or counteract treatment.

Patients should not stop a beta-blocker abruptly, as this can cause rebound increases in heart rate and blood pressure and, in people with coronary disease, may provoke angina. Any change should be planned with the prescriber.

Common side effects listed in the product information include headache, dizziness, tiredness, pins and needles and gastrointestinal upset. People with asthma, very slow heart rates or certain heart conduction problems may not be suitable for beta-blockers.

If you develop yellowing of the skin, dark urine, marked fatigue, swelling of the legs or a significant reduction in urine output, contact your GP promptly, whatever medicine you are taking.

Nebivolol, exercise and sport

Beta-blockers lower the maximum heart rate and can reduce peak exercise capacity, particularly in endurance activities. Nebivolol's vasodilating properties may make it somewhat better tolerated than older agents, but people still often notice a change in how training feels.

Heart-rate-based training zones need adjusting on beta-blockers. Perceived exertion is often a more useful guide, and many cardiac rehabilitation programmes teach this approach.

Beta-blockers are prohibited in competition in certain sports under the World Anti-Doping Agency list, mainly precision sports such as archery and shooting, and in some others out of competition as well. Athletes who need nebivolol for a medical condition should check with UK Anti-Doping about whether a Therapeutic Use Exemption is required.

Under no circumstances should nebivolol be used without a prescription to steady the hands or calm nerves before competition. Apart from anti-doping rules, unsupervised use carries real cardiovascular risks.

Conclusions of the editorial team

Nebivolol relies heavily on the liver for its metabolism, which is why significant liver impairment is a contraindication in UK labelling.

Kidney impairment does not rule it out, but it calls for a cautious start and regular monitoring by the prescriber.

Direct damage to the liver or kidneys from nebivolol appears rare; the key practical issues are drug interactions, abrupt withdrawal and individual suitability.

For further reading, the editorial team recommends our articles on beta-blockers and exercise, on how blood pressure medicines affect the kidneys, and on understanding liver function test results.

References

1. Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491–1499.
2. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225.
3. Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-generation beta-adrenergic blocker. Ann Pharmacother. 2006;40(7–8):1353–1360.
4. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
5. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline NG136. London: NICE; 2019.
6. Nebivolol 5 mg tablets: Summary of Product Characteristics. Electronic Medicines Compendium (emc).